NCT02792114: T-Cell Therapy for Advanced Breast Cancer

NCT02792114
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Untreated or active CNS metastases- see trial for details
https://ClinicalTrials.gov/show/NCT02792114

Comments are closed.

Up ↑